文献速递肿瘤 PET/CT

[68Ga]Ga-DOTA-FGFR1与[18F]FDG PET/CT诊断肺癌的头对头比较

A head-to-head comparison of [68Ga]Ga-DOTA-FGFR1 and [18F]FDG PET/CT in the diagnosis of lung cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-11-09

前瞻性研究纳入101例临床高度怀疑肺癌患者,在6天内分别行[68Ga]Ga-DOTA-FGFR1与[18F]FDG PET/CT,以组织病理学和临床随访为参考标准。结果显示[68Ga]Ga-DOTA-FGFR1对原发肿瘤特异性更高(52% vs 28%,P=0.031),对淋巴结转移的特异性、准确性和PPV更高,但对淋巴结和远处转移的敏感性低于[18F]FDG。

要点

  • 良性肺病变中[68Ga]Ga-DOTA-FGFR1的TBR和SUVmax均低于[18F]FDG(P<0.001)。
  • [68Ga]Ga-DOTA-FGFR1对原发肿瘤特异性52% vs [18F]FDG 28%(P=0.031)。
  • [68Ga]Ga-DOTA-FGFR1对淋巴结转移敏感性低于[18F]FDG(P<0.001)。

核心结论

  • [68Ga]Ga-DOTA-FGFR1 PET/CT对原发性肺癌检测的特异性高于[18F]FDG PET/CT。
  • [68Ga]Ga-DOTA-FGFR1 PET/CT对淋巴结转移的诊断准确性、特异性和NPV更高,但对转移性病变的诊断敏感性低于[18F]FDG PET/CT。
  • 因此,[68Ga]Ga-DOTA-FGFR1在一定程度上可作为[18F]FDG的有效补充。

研究设计与样本

  • 前瞻性研究,于2023年3月至2023年7月开展。
  • 招募临床高度怀疑肺癌的患者,共纳入101例参与者(平均年龄63.267±9.344岁,范围39-86岁)。
  • 每位参与者在6天内接受[68Ga]Ga-DOTA-FGFR1和[18F]FDG PET/CT扫描。
  • 以组织病理学和临床随访结果作为最终诊断的参考标准。

主要发现

  • 良性肺病变中,[68Ga]Ga-DOTA-FGFR1的TBR低于[18F]FDG(2.924 vs 5.705,P<0.001),SUVmax亦低于[18F]FDG(1.395 vs 4.014,P<0.001)。
  • 良性淋巴结中,[68Ga]Ga-DOTA-FGFR1的TBR低于[18F]FDG(0.880 vs 1.25,P<0.001)。
  • [68Ga]Ga-DOTA-FGFR1对原发肿瘤的诊断特异性高于[18F]FDG(52% vs 28%,P=0.031)。
  • [68Ga]Ga-DOTA-FGFR1检测淋巴结转移的特异性、准确性和PPV分别为82.54%、78.66%、53.73%,均高于[18F]FDG(分别为53.80%,P<0.001;63.15%,P<0.001;38.35%,P=0.003)。
  • [68Ga]Ga-DOTA-FGFR1诊断淋巴结转移和远处转移的敏感性不如[18F]FDG PET/CT(P<0.001,P=0.016)。

关键数值与推荐

  • 良性肺病变:[68Ga]Ga-DOTA-FGFR1 TBR 2.924 vs [18F]FDG 5.705(P<0.001)。
  • 良性肺病变:[68Ga]Ga-DOTA-FGFR1 SUVmax 1.395 vs [18F]FDG 4.014(P<0.001)。
  • 良性淋巴结:[68Ga]Ga-DOTA-FGFR1 TBR 0.880 vs [18F]FDG 1.25(P<0.001)。
  • 原发肿瘤特异性:[68Ga]Ga-DOTA-FGFR1 52% vs [18F]FDG 28%(P=0.031)。
  • 淋巴结转移:[68Ga]Ga-DOTA-FGFR1特异性82.54%、准确性78.66%、PPV 53.73%,分别高于[18F]FDG的53.80%(P<0.001)、63.15%(P<0.001)、38.35%(P=0.003)。

临床怎么用

  • [68Ga]Ga-DOTA-FGFR1 PET/CT对原发性肺癌检测的特异性高于[18F]FDG PET/CT。
  • [68Ga]Ga-DOTA-FGFR1 PET/CT对淋巴结转移的诊断准确性、特异性和NPV更高,但对转移性病变的敏感性低于[18F]FDG PET/CT。
  • 作者认为[68Ga]Ga-DOTA-FGFR1在一定程度上可作为[18F]FDG的有效补充。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to compare the diagnostic value of [68Ga]Ga-DOTA-FGFR1 and [18F]FDG PET/CT in the evaluation of lung cancer patients. METHODS: A prospective study was conducted between March 2023 and July 2023. Patients with high clinical suspicion of lung cancer were recruited. Each participant underwent PET/CT scanning using [68Ga]Ga-DOTA-FGFR1 and [18F]FDG within 6 days. Histopathology and clinical follow-up results serve as reference criteria for final diagnosis. We used a paired samples t-test or a Wilcoxon signed-rank test to compare the uptake of [68Ga]Ga-DOTA-FGFR1 and [18F]FDG. The diagnostic performance between the two tracers was compared using the McNemar χ² test. RESULTS: A total of 101 participants were included (mean age 63.267 ± 9.344 [range 39-86 years]). In benign lung lesions, [68Ga]Ga-DOTA-FGFR1 had lower TBR and SUVmax than [18F]FDG (2.924 vs. 5.705, P < 0.001;1.395 vs. 4.014, P < 0.001). The TBR of [68Ga]Ga-DOTA-FGFR1 in benign lymph nodes was also lower than [18F]FDG (0.880 vs. 1.25, P < 0.001). [68Ga]Ga-DOTA-FGFR1 had a higher diagnostic specificity for primary tumors than [18F]FDG (52% vs. 28%, P = 0.031). The specificity, accuracy, and PPV of [68Ga]Ga-DOTA-FGFR1 for detecting lymph node metastasis were 82.54%, 78.66%, and 53.73%, respectively, higher than that of [18F]FDG (53.80%, P < 0.001, 63.15%, P < 0.001 and 38.35%, P = 0.003). However, its sensitivity in the diagnosis of lymph node and distant metastasis was not as good as [18F]FDG PET/CT (P < 0.001, P = 0.016, respectively). There was a significant correlation between [68Ga]Ga-DOTA-FGFR1 uptake and FGFR1 expression (Spearman r = 0.6901, p < 0.0001). CONCLUSIONS: [68Ga]Ga-DOTA-FGFR1 PET/CT had higher specificity than [18F]FDG PET/CT for the detection of primary lung cancer. In addition, [68Ga]Ga-DOTA-FGFR1 PET/CT also had higher diagnostic accuracy, specificity, and NPV for lymph node metastasis, but its diagnostic sensitivity for metastatic lesions was lower than [18F]FDG PET/CT. Therefore, [68Ga]Ga-DOTA-FGFR1 can be used as an effective supplement to [18F]FDG to a certain extent.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Yuan H, Chen X, Zhao X, et al. A head-to-head comparison of [68Ga]Ga-DOTA-FGFR1 and [18F]FDG PET/CT in the diagnosis of lung cancer. Eur J Nucl Med Mol Imaging. 2024. PMID: 39516377. doi:10.1007/s00259-024-06976-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。